Inavolisib

伊那利塞

Report date: 2026/05/12 20:00:17
NME

Base Information

Drug NameInavolisib
Drug Alias NameItovebi伊赫莱RG-6114GDC-0077RO-7113755
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase alpha inhibitors
TargetsPhosphatidylinositol 3 kinase alpha
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursHepatic Insufficiency +[10] 
Global Approved IndicationsMetastatic breast cancerBreast Neoplasms
Approved Indications in ChinaMetastatic breast cancerBreast Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2024/10/10
Country/TerritoryCzechiaBelgiumCanada +[45] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesFoundation Medicine IncRoche Pharma AgRoche Pharma (Schweiz) Ag +[10] 
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursHepatic Insufficiency +[9] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG